Tvardi Therapeutics, Inc.

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule therapeutics targeting Signal Transducer and Activator of Transcription 3 (STAT3). The firm develops treatments for inflammatory and proliferative diseases with significant unmet need driven by dysregulated STAT3 signaling. Its development pipeline centers on two investigational small molecules: TTI-101, a direct STAT3 inhibitor in clinical trials for hepatocellular carcinoma and idiopathic pulmonary fibrosis, and TTI-109, an oral phosphate prodrug engineered to enhance systemic delivery and tolerability. As a clinical-stage development enterprise without approved commercial products, the company does not currently sell directly to commercial end users or consumers.

Clinical development operations for its candidate molecules span medical trial centers across the United States, including a Phase 2 study conducted across 28 domestic trial sites. The provided text contains no mention of the company's corporate headquarters location or physical corporate facilities beyond these clinical trial locations.

Summary of the business section of Tvardi Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 12 full-time employees, 8 of whom are involved in research and development activities.”